🇺🇸 FDA
Patent

US 8299087

Compositions and methods for inhibition of the JAK pathway

granted A61KA61K31/506A61K31/5375

Quick answer

US patent 8299087 (Compositions and methods for inhibition of the JAK pathway) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Rigel Pharmaceuticals, Inc.
Grant date
Tue Oct 30 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Oct 25 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/506, A61K31/5375, A61K31/538, A61K31/5383